CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 4, 2014
Result type: Reports
Project Number: SR0375-000
Product Line: Reimbursement Review

Generic Name: Icatibant

Brand Name: Firazyr

Manufacturer: Shire Human Genetic Therapies (Canada) Inc.

Therapeutic Area: Hereditary angioedema

Indications: Angioedema, hereditary

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 19, 2014

Recommendation Type: List with clinical criteria and/or conditions